Healthcare Services

One of the Major Drivers of the Acromegaly Market Global Report 2026 Market Is the Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Acromegaly Market At The End Of The 2026–2030 Forecast Period?

The acromegaly market has experienced swift expansion in recent years. It is anticipated to increase from $2.56 billion in 2025 to $3.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.5%. The historical growth of this market can be linked to several factors, including the constrained availability of diagnostic tools for acromegaly, a rising occurrence of growth hormone disorders, the development of hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and an increasing understanding of rare endocrine disorders.

The acromegaly market is projected to experience substantial expansion in the coming years. It is forecast to reach $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This growth during the forecast period is primarily driven by the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment availability, the growing embrace of precision medicine strategies, the proliferation of homecare and outpatient treatment models, and the incorporation of digital health and remote monitoring technologies. Key trends anticipated within this period involve the greater uptake of growth hormone measurement and IGF-I testing, an increasing application of somatostatin analogues and dopamine agonists, the broader implementation of minimally invasive surgery and radiation therapy, a heightened emphasis on individualized treatment strategies for patients, and improved awareness and early diagnostic initiatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Acromegaly Market?

The acromegaly market is anticipated to experience growth driven by the increasing incidence of hormonal diseases such as diabetes. Hormonal diseases, also recognized as endocrine disorders, are medical conditions that arise from a malfunction in the endocrine system. Diabetes represents one of the most prevalent and significant hormonal diseases. Acromegaly, alongside other endocrine diseases, can be caused by the excessive production of certain hormones, including growth hormone or cortisol. Furthermore, about 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus due to the effect of elevated growth hormone on insulin synthesis. For instance, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2024, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22% between March 2022 and March 2023, while for type 2 diabetes, it rose by 21%. During the same period, the percentage achieving target HbA1c levels ascended to 37.9%, which marked the highest value ever reported by the National Diabetes Audit (NDA). Consequently, the rising number of hormonal diseases is a key factor propelling the growth of the acromegaly market.

What Segment Types Make Up The Acromegaly Market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parental, Other Routes Of Administration

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Which Market Trends Are Creating New Opportunities In The Acromegaly Market?

Major companies operating in the acromegaly market are actively pursuing the development of innovative products and solutions, including generic lanreotide, to expand treatment possibilities and enhance patient outcomes. Generic lanreotide refers to an unbranded formulation of the drug used to manage acromegaly and specific neuroendocrine tumors, acting as a somatostatin analogue to reduce growth hormone secretion and improve patient accessibility to effective therapeutic options. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, thereby improving access to crucial therapy for patients requiring these treatments.

Who Are The Key Players Driving Competition In The Acromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Read the full acromegaly market report here:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Regions Are Projected To Dominate The Acromegaly Market In The Coming Years?

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acromegaly Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Browse Through More Reports Similar to the Global Acromegaly Market 2026, By The Business Research Company

thrombophilia global market report

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

hormone therapy global market report

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

mastopexy global market report

https://www.thebusinessresearchcompany.com/report/mastopexy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795